On the basis of the cardioprotective effect of NRG-1, the development of drugs or therapeutic strategies targeting the NRG-1/ErbB signaling pathway may lead to innovative avenues for the treatment of ASCVD. The gene discussed is NRG1; the disease is atherosclerosis.